

### Daftar Pustaka

1. Perhimpunan Dokter Paru Indonesia. Hospital Acquired Pneumonia (HAP) dan Ventilator Associated Pneumonia (VAP). Edisi II. Badan Penerbit FKUI. Jakarta 2018: pp 1-52.
2. Ward BW, Clarke TC, Nugent CN, Schiller JS. Early release of selected estimates based on data from the 2015 National Health Interview Survey. National Center for Health Statistics. May 2017. Available : <http://www.cdc.gov/nchs/nhis.htm>.
3. Perhimpunan Dokter Paru Indonesia, 2014. Pneumonia Komunitas. Pedoman Diagnosis dan Penatalaksanaan Di Indonesia. Edisi kedua. 2014.p 1-20.
4. De Jager CPC, Wever PC, Gemen EFA, Kusters R, Van Gageldonk-Lafeber AB, Tom Van der Poll T, and Laheij RJF. The Neutrophil-Lymphocyte Count Ratio in Patients with Community Acquired Pneumonia. PLoS One. 2012;7(10).
5. Schuetz P, Amin DN, Greenwald JL. Role of procalcitonin in managing adult patients with respiratory tract infections. Chest. 2012;141:1063-73.
6. Muller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, et al. ProHOSP Study Group. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010;138:121-9.
7. Menendez R, Martinez R, Reyes S, Mensa J, Filella X, Marcos MA, et al. Biomarkers improve mortality prediction by prognostic scales in community acquired pneumonia. Thorax. 2009; 64.
8. Schuetz P, Suter-Widiabetes mellituser I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B. Prognostic value of procalcitonin in communityacquired pneumonia. Eur Respir J. 2011;37:384-92.
9. Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartman O, Wegscheider K, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010;36(3):601-7.

10. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions : past, present and future. *BMC Medicine* 2011; 9:107.
11. Borovac DN, Pejcic T, Petkovic TR, Dordevic V, Dordevic I, Stankovic I, et al. New marker in Prognosis of Severe Community Acquired Pneumonia. *Acta Facultatis Medicae Naissensis*. 2011; 28(3).
12. Holub M, Beran O, Kasprikova N, Chalupa P. Neutropil to Lymphocyte Count Ratio as a Biomarker of Bacterial Infection. *Central European Journal of Medicine* 2011;1-4.
13. Yang T, Wan C, Wang H, Qin J, Chen L, Shen Y, et al. The prognostic and risk stratified value of neutrophil-lymphocyte count ratio in Chinese patients with community-acquired pneumonia. *European Journal of Inflammation* 2017; 15:22-27.
14. Soedarsono. Pneumonia. In: Wibisono MJ, Winariani, Hariadi S. *Buku Ajar Ilmu Penyakit Paru*. Surabaya: Departemen Ilmu Penyakit Paru FK Unair; 2010;pp.149-179.
15. Kalil AC, Metersky ML, Klompas M. Management of adult with Hospital acquired pneumonia and ventilator associated pneumonia: 2016 clinical practice guideline by the infectious disease society of America and the American thoracic society. *Clin Infect Dis* 2016;63(5): 61-111.
16. Marrie TJ, Campbell GD, Walker DH, Low DE. Pneumonia. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL. *Harrison's principle of internal medicine*. 16<sup>th</sup> Ed. USA: McGRaw-Hill; 2005: pp. 1528-1530.
17. Riches DW, sawyer RT, Fenton MJ, Martin TR. Innate Immunity in The Lungs. In D M, editor. *Textbook of Respiratory Medicine*. 5th ed. Philadelphia: Saunders Elseviier; 2010. p. 255-257
18. Opitz B, Laak V, Eitel J, Suttorp N. Innate Immune Recognition in Infectious and Noninfectious Diseases of the Lung. *American Journal Of Respiratory And Critical Care Medicine* 2010;181:1294-1295.
19. Chong DL, Sriskandan S. Pro-Inflammatory Mechanism in Sepsis. In Hewarld H, Egesten A, eds. *Sepsis pro-inflammatory and Anti Inflammatory Responses*. 2011;87-107.
20. Russel JA, Boyd J, Nakada T. Molecular mechanisms of Sepsis. In Hewarld H, Egesten A, eds. *Sepsis pro-inflammatory and Anti Inflammatory Responses*. 2011;87-107.

21. Singayanagam JD, Chalmers and Hill AT. Severity assessment in Community Acquired Pneumonia. *Q J Med* 2009;102:379–388.
22. Mandell LA, Wunderik RG, Arzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/ American Thoracic Society Consensus Guidelines on The Management of Community Acquired Pneumonia in Adults. *Clinical Infectious Diseases* 2007;44:27-72
23. Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. *Thorax* 2006;61(5):419-24.
24. Mira JP, Max A, Burgel PR. The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy. *Critical Care* 2008;12(Suppl 6):S5.
25. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. *Critical Care* 2010;14(1):1.
26. Morgenthaler NG, Struck J, Fischer-Schulz C, Seidel-Mueller E, Beier W, Bergmann A. Detection of procalcitonin (PCT) in healthy controls and patients with local infection by a sensitive ILMA. *Clin Lab.* 2002;48:263-70
27. Summah H dan Qu JM. Biomarkers: A Definite Plus in Pneumonia. Hindawi. 2009: 1-9.
28. Christ-Crain M, Stolz D, Bingisser R. PCT-guided antibiotic therapy in CAP. *Am J Resp and Crit Care Med.* 2006;174: 84–93
29. Hedlund J dan L. Hansson O. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. *Infection.* 2000; 28 (2): 68– 73.
30. Muller F, Christ-Crain M, Bregenzer T.. ProHOSP Study Group. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. *Chest.* 2010;138:121-9.
31. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. *Clin Inf Dis.* 2004; 39 (2): 206–217.
32. Hedlund J dan L. Hansson O. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. *Infection.* 2000; 28 (2): 68– 73.

33. Grossman R. Community-acquired pneumonia: the future is now. The 14<sup>th</sup> International Meeting on Respiratory Care Indonesia. 2012 October 3<sup>rd</sup>-4<sup>th</sup>. Jakarta, Indonesia
34. Self WH, Grijalva CG, Williams DJ. Procalcitonin as an early marker of the need for invasive respiratory or vasopressor support in adults with Community-Acquired Pneumonia. *Chest*.2016; 440: 1-15.
35. Huang DT, Weissfeld LA, Kellum JA. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. *Ann Emerg Med* 2008; 52:48-58.
36. Ramirez P, Ferrer M, Marti V. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. *Crit Care Med*.2011; 39: 2211-2217.
37. Kutz A, Briel M, Christ-Crain M. Prognostic value of procalcitonin in respiratory tract infections across clinical settings. *Crit Care*. 2015;19:74.
38. Pfister R, Kochanek M, Leygeber T, Brun-Buisson C, Cuquemelle E, Machado MBP. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a retrospective cohort study, systematic review and individual patient data meta-analysis. *Crit Care*.2014;18:R44.
39. Nugroho A., Suwarman, Nawawi A. M.. Hubungan antara Rasio Neutrofil-Limfosit dan Skor Sequential Organ Failure Assesment pada Pasien yang Dirawat di Ruang Intensive Care Unit. *Jurnal Anestesi Perioperatif*. 2013;3: 189–196.
40. Zahorec R. Ratio of neutrophil to lymphocyte counts rapid and simple parameter of systemic inflammation and stress in critically ill. *Clinical Report* 2001;102:5-14.
41. Holub M, Beran O, Kaspříková N, Chalupa P. Neutrophil to lymphocyte count ratio as a biomarker of bacterial infections. *Central European Journal of Medicine* 2011;1-4.
42. Hotchkis RS, Karl IE. The Pathophysiology and Treatment of Sepsis. *The New England Journal* 2003;348(2):138-150.
43. Stearns-Kurosawa DJ. The Pathogenesis of Sepsis. *Annu Rev Pathol* 2011;(6):19-18.
44. Lowsby R, Gomes C, Jarman I. Neutrophil to lymphocyte count ratio as an early indicator of blood stream infection in the emergency department. *Emerg Med J published* 2014. pp.1-5.

45. Xia Y, Guo X, Ji Chen Q. Neutrophil count to lymphocyte count ratio is a potential diagnostic index for bacteremia in adult. *Life Science Journal*. 2014; 11(1):17-177.
46. Gurol G, Hakki I, Terzi HA, Atasoy AR, Ozbek A, Kroglu M. Are There Standardized Cutoff Values for Neutrophil-Lymphocyte Ratios in Bacteremia or Sepsis? *Journal of Microbiology and Biotechnology* 2014;1-8.
47. Imtiaz F, Shafique K, Mirza S, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population". *International Archives of medicine* 2012;5(2):1-6.
48. Jiu-Xin Qu, Li Gu, Zeng Hui Pu, Xiao-Min Yu, Ying-Mei Liu, Ran Li, Yi-Min, Wang, Bin Cao, Ccheng Wang and For Beijing Network for Adult Community-Acquired Pneumonia (BNACAP). Viral Etiology of Community-Acquired Pneumonia among Adolscents and Adults with Mild or Moderate Severity and Its Relation to Age and Severity. *BMC Infectious Disease* (2015) 15:89
49. Antoni Torres, Willy E Peetermans, Giovanni Viegi, Francesco Blasi. Risk Factors for Community-Acquired Pneumonia in Adults in Europe: A Literature Review. *Thorax* 2013;68:1057-1065.
50. Yukai Huang, Aihua Liu, Ling Liang, Jiawei Jiang, Haihua Luo, Weiming Deng, Guohui Lin, Maosheng Wu, Tianwang Li, Yong Jiang. Diagnostic Value of Blood Parameters for Community-Acquired Pneumonia. *International Immunopharmacology* 64 (2018) 10-15.
51. Mahendra M, Jayaraj BS, Limaye S, Chaya SK, Dhar R, Mahesh PA. Factors Influencing Ceverity of Community-Acquired Pneumonia. *Lung-India*. 2018 Jul-Aug; 35(4): 284-289.
52. Elza Febria Sari, C. Martin Rumende, Kuntjoro Harimurti. Factors Related to Diagnosis of Community-Acquired Pneumonia in the Elderly. *Jurnal Penyakit Dalam Indonesia* Vol. 3, No. 4 Desember 2016.
53. Krishna Kumar Yadav, Shally Awasthi, Lalit Takia, Jyotsna Agarwal, G. G. Agarwal. Procalcitonin and C-Reactive Protein in WHO Defined Severe and Very Severe Community-Acquired Pneumonia: A Hospital Based Cross-Sectional Study. *Clinical Epidemiology ang Global Health* 3 (2015) s3-s9.